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Abstract  
Aims: To assess levels of the calcium permeable transient receptor potential cation channel, 
subfamily melastatin, member 8 (TRPM8) in breast cancer molecular subtypes and to assess the 
consequences of TRPM8 pharmacological inhibition with AMTB (an inhibitor of TRPM8) on 
breast cancer cell lines.  
Materials and Methods: Cell viability and migration of breast cancer cells was determined using 
MTS assays and wound healing assays, respectively. RNA-Seq analysis of breast tumours and 
qPCR in breast cancer cell lines were used to assess mRNA levels of ion channels. Membrane 
potential assays were employed to assess the effects of AMTB against specific voltage gated 
sodium channels (NaV). 
Key findings: TRPM8 levels were significantly higher in breast cancers of the basal molecular 
subtype. AMTB decreased viable cell number in MDA-MB-231 and SK-BR-3 breast cancer cell 
lines (30 and 100 µM), and also reduced the migration of MDA-MB-231 cells (30 µM). However, 
these effects were independent of TRPM8, as no TRPM8 mRNA was detected in MDA-MB-231 
cells. AMTB was identified as an inhibitor of NaV isoforms. NaV1.1-1.9 were expressed in a 
number of breast cancer cell lines, with NaV1.5 mRNA highest in MDA-MB-231 cells compared to 
the other breast cancer cell lines assessed. 
Significance: TRPM8 levels may be elevated in basal breast cancers, however, TRPM8 expression 
appears to be lost in many breast cancer cell lines. Some of the effects of AMTB attributed to 
TRPM8 may be due to effects on NaV channels. 
 
Key words: AMTB, breast cancer, TRPM8, sodium channels 
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Introduction  
Changes in cytosolic free calcium ([Ca
2+
]CYT) are often critical for events important in cancer 
progression (1, 2). Altered expression of specific calcium permeable ion channels has been widely 
reported in cancers and/or cancer cell lines originating from the lung, prostate and breast (3-7). In 
some cases, such changes are even specific to the cancer clinical subtype, such as the 
overexpression of the transient receptor potential cation channel subfamily V member 6 (TRPV6) 
channel in estrogen receptor negative breast cancers and those of the basal molecular subtype (8). 
The basal molecular subtype of breast cancer is of particular interest due to its overlap with breast 
cancers that lack the expression of receptors representing current targets for targeted therapies, such 
as the estrogen and human epidermal growth factor 2 (HER2) receptors (9, 10). 
 
TRPM8 is a member of the TRP ion channel family and is expressed in primary sensory neurons 
where it plays an important role in cold sensation (11). The properties of TRPM8 in specific 
neuronal sensory pathways have seen its identification as a target for a diverse range of conditions 
including pain, migraine and cough (12-14). However, despite the importance of TRPM8 as a 
sensor in neurons, it was actually first identified through a study assessing the overexpression of 
proteins in the prostate, which also demonstrated elevated levels in cancers of the prostate, lung, 
colon and breast (15). Subsequent to this report, a variety of studies have explored in great depth the 
contribution of TRPM8 to prostate cancer cell growth and invasion and the potential role of TRPM8 
modulators to control prostate cancer disease progression and/or TRPM8 as a biomarker (16-20).  
 
Despite the first report of TRPM8 overexpression in breast cancer occurring in 2001 (15), there 
have been limited studies of TRPM8 in the context of possible associations with breast cancer 
subtypes, the role of TRPM8 in breast cancer cells and the suitability of this ion channel as a target 
for breast cancer therapy (21, 22). An agent which may be useful in defining the possible role of 
TRPM8 in breast cancer and as a proof of concept tool for targeting TRPM8 in breast cancer 
therapy is the TRPM8 inhibitor, N-(3-aminopropyl)-2-{[(3-methylphenyl) methyl]oxy}(20)-N-(2-
thienylmethyl)benzamide (AMTB) (23). AMTB, a 2-benzyloxy-benzoic acid amide derivative (18), 
has been used as a TRPM8 pharmacological inhibitor in a variety of studies (23-25) and has been 
reported to inhibit the migration of LNCaP, PC3 and DU145 prostate cancer cell lines (25). TRPM8 
has also been reported to regulate migration, proliferation and also angiogenesis processes (20, 26-
32).  However, AMTB has not been assessed in breast cancer cell lines. 
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Hence, in this study, we sought to define the expression of TRPM8 in breast cancer molecular 
subtypes and assess the consequences of TRPM8 pharmacological inhibition in breast cancer cell 
lines. These studies yielded the unexpected result that some of the reported effects of AMTB in a 
variety of disease models may be independent of TRPM8 and could rather be a consequence of the 
ability of AMTB to inhibit voltage gated sodium channels (NaV) of the NaV1 class. 
 
Materials and Methods: 
 
Analysis of TRPM8 expression in breast tumours 
RNA-Seq gene expression profiles in human breast tumours (n = 506) from The Cancer Genome 
Atlas (TCGA) study (33) were assessed as previously described (34). Gene expression of TRPM8 
in 84 basal-like, 58 HER2 enriched, 233 Luminal A, and 131 Luminal B tumours were evaluated. 
Statistical significance was measured using Kruskal-Wallis test with Dunn’s post-test.  
 
Cell Culture 
The human breast cancer cell lines used this study: MDA-MB-231, MCF-7 and HCC1569 were 
purchased from American Type Culture Collection; SK-BR-3, T-47D and ZR-75-1 cell lines were a 
kind donation from the late Professor Rob Sutherland (Garvan Institute, Sydney) and MDA-MB-
468 cells were a generous gift from Dr Chanel Smart (The University of Queensland Centre for 
Clinical Research). MDA-MB-231 cells and SK-BR-3 cells were cultured as previously described 
(35, 36) in antibiotic-free media and routine mycoplasma contamination testing was carried out 
using the MycoAlert Mycoplasma Detection Kit (LT07-218, Lonza Inc). 
 
Pharmacological agents 
AMTB was purchased from Sigma-Aldrich (SML0103). Stock solutions were prepared by 
dissolving compounds in dimethyl sulfoxide (DMSO) (D8418, Sigma-Aldrich) or sterile distilled 
water and aliquots were stored at 4°C or -20°C. Lidocaine (N-(2,6-dimethylphenyl)acetamide) stock 
solution was purchased from Sigma-Aldrich (L7757). 
 
 
Cell viability assay 
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CellTiter 96
® 
AQueous One Solution Cell Proliferation Assay (G3580, Promega) was used to 
determine cell viability. Cells were cultured in antibiotic-free media and plated in 96-well plates at a 
density of 5,000 cells per well for MDA-MB-231 and 6,000 cells per well for SK-BR-3 cells. 
Pharmacological compounds/toxins were diluted to the appropriate concentrations in cell culture 
media and added to the cells at 24 h and 72 h post plating. Control wells were treated with 0.1% 
vehicle (DMSO or absolute ethanol) or antibiotic-free media. MTS assays were performed 96 h post 
plating using CellTiter 96
®
 AQueous One Solution Reagent (Promega). Absorbance at 490 nm was 
measured using a micro-plate reader ((iMark, BioRAD). 
 
In vitro scratch assay 
MDA-MB-231 cells (17 000 cells per well) were seeded in 96-well plates and incubated at 37°C, 
5% CO2 for 48 h. The WoundMaker™ instrument (Essen Biosciences) was used to produce an 
equal sized scratch in the cell monolayer of all wells of the plate. Cells were washed twice with 
fresh media and immediately treated with various concentrations of AMTB for 24 h. Images of the 
centre of each well were acquired with a JuLI
TM
 Stage live cell imaging system (NanoEntek) (10X 
objective), 24 h post-treatment. Analysis of wound closure (confluence) was performed using 
JuLI
TM
 Stage automated cell imaging system software (V0.0, NanoEntek). Confluency results were 
normalised to a control well (media treatment) representing the highest confluence at 24 h. 
 
RNA isolation and real-time RT-PCR 
Total RNA was isolated and purified using a RNeasy Plus Mini Kit (74136, Qiagen). Purified RNA 
was reverse transcribed using Omniscript RT Kit (Qiagen); random primers (C1181, Promega) and 
RNAase inhibitor (N2111, Promega) were purchased separately. Real-time PCR was performed 
using TaqMan
®
 Universal PCR Master Mix (2X) and TaqMan
®
 gene expression assays purchased 
from Life Technologies. Gene expression assays: SCN1A/NaV1.1 (Hs00374696_m1), 
SCN2A/NaV1.2 (Hs01109877_m1), SCN3A/NaV1.3 (Hs00366902_m1), SCN4A/NaV1.4 
(Hs01109480_m1), SCN5A/NaV1.5 (Hs00165693_m1), SCN8A/NaV1.6 (Hs00274075_m1), 
SCN9A/NaV1.7 (Hs00161567_m1), SCN10A/NaV1.8 (Hs01045137_m1), SCN11A/NaV1.9 
(Hs00204222_m1), TRPM8 (Hs01066597_m1) and endogenous control for 18S rRNA (4319413E) 
were used in this study. Assays were performed using a StepOne Plus instrument (Applied 
Biosystems) under universal cycling conditions and data were analysed using StepOne Plus 
Software, version 2.2.2 (Applied Biosystems). The relative quantification or comparative CT (cycle 
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threshold) method (37) was used to determine relative mRNA levels with data normalised to 18S 
rRNA.  
Human TRPM8 cDNA clone (pCMV6-XL5-hTRPM8, un-tagged, homo-sapiens, clone MGC:2849, 
complete cds, NCBI RefSeq: BC001135.1, 10 μg, Cat#: SC13793, Origene Technologies Ltd) was 
used as a positive control for TRPM8 real-time RT-PCR assays.  
 
FLIPR membrane potential assay 
HEK293 cells heterologously expressing human NaV1.1–1.8 (SB Drug Discovery, Glasgow, UK) 
were cultured in MEM containing 10% v/v FBS and selection antibiotics as recommended by the 
manufacturer. Cells were grown in a humidified 5% CO2 incubator at 37°C, grown to 70–80% 
confluence, and passaged every 3-4 days using TrypLE Express (Invitrogen). Cells were seeded in 
384-well plates (Corning) at a density of 10,000-15,000 cells per well and cultured for 48 h. 
Membrane potential dye (Molecular Devices) was diluted in physiological salt solution (PSS; 140 
mmol/L NaCl, 11.5 mmol/L glucose, 10 mmol/L HEPES, 5.9 mmol/L KaCl, 1.4 mmol/L MgCl2, 
1.2 mmol/L NaH2PO4, 5 mmol/L NaHCO3, 1.8 mmol/L CaCl2, pH 7.4). Growth media was 
removed from the cells, 20 µL dye/well added and cells incubated in the dark at 37°C for 30 min. A 
two-addition FLIPR protocol consisting of addition of AMTB, incubation for 5–10 min and 
addition of veratridine (20-60 μM) to activate NaV1.1-1.7 or deltamethrin (150 μM) was used to 
activate NaV1.8. The change in fluorescence was measured (excitation 515–545 nm, emission 565–
625 nm) every 1-2 s for 5-30 min after addition of agonists using the fluorescence imaging plate 
reader FLIPR TETRA (Molecular Devices). To quantitate the effect of test compounds on NaV 
responses, the area under the curve (AUC) corresponding to 5 min after the addition of veratridine 
or maximum response corresponding to 30 min after the addition of deltamethrin was computed 
using ScreenWorks (Molecular Devices, Version 3.2.0.14). 
 
Statistical Analysis 
Statistical analysis was performed using GraphPad Prism version 6.04 for Windows, unless 
otherwise specified.  
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Results: 
 
TRPM8 levels are elevated in basal-like breast cancers 
TRPM8 levels were significantly higher in basal-like breast tumours, compared to the luminal A, B 
and HER2-enriched subtypes (Figure 1). Considerable variation in TRPM8 levels was also 
observed within the basal-like subtype, with the sample showing the highest TRPM8 expression 
level having 476 times more TRPM8 transcript than the median level among the basal-like samples. 
Although the most striking elevation was detected in the basal-like breast tumour samples, the 
HER2-amplified group also had higher TRPM8 levels than both of the luminal subtypes. 
 
  
Figure 1: TRPM8 expression in breast cancer clinical samples. Gene expression (Reads Per 
Kilobase of transcript per Million (RPKM)) of TRPM8 in 506 breast tumours from TCGA breast 
cancer RNA-Seq data, classified according to breast tumour subtypes. TRPM8 is over-expressed the 
basal-like subtype compared to HER2 enriched and luminal A/B subtypes. Horizontal lines 
represent median levels for each subtype, statistical significance was determined using Kruskal-
Wallis test with Dunn’s post-test; *** P < 0.001; ** P < 0.01; * P < 0.05.  
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AMTB decreases the proliferation and migration of breast cancer cells via a TRPM8 
independent mechanism 
Treatment of MDA-MB-231 and SK-BR-3 breast cancer cells with the TRPM8 inhibitor AMTB 
reduced cell viability by approximately 70% at 30 and 100 µM, with IC50 values of 23.7 µM and 
17.3 µM in MDA-MB-231 and SK-BR-3 cells, respectively (Figure 2A and B). In vitro scratch 
assays showed that AMTB (30 µM) also significantly decreased the migration of MDA-MB-231 
breast cancer cells (Fig 2C). However, this effect was not due to TRPM8, since assessment of 
TRPM8 mRNA levels in a variety of breast cancer cell lines representing distinct molecular 
subtypes (38, 39), revealed little or no TRPM8 mRNA (Table 1), including in SK-BR-3 and MDA-
MB-231 cells where effects by AMTB were observed. Therefore, the effects of AMTB, a reported 
selective TRPM8 inhibitor (23), at a concentration (30 µM) used in other model systems (18), 
occurred independently of TRPM8 inhibition in these breast cancer cell lines. The possibility of off-
target effects of AMTB was therefore investigated.  
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Figure 2: AMTB reduces cell viability and migration of breast cancer cells. Concentration-
response curves for AMTB in MDA-MB-231 (A) and SK-BR-3 (B) breast cancer cells. Cells were 
incubated with AMTB (0 – 100 µM) for 72 h and an MTS assay was used to approximate viable 
cell number. Absorbance values (490 nm) were normalised to control treated cells and plotted using 
non-linear regression curve fit: log (inhibitor) vs response – variable slope (four parameters). Data 
show mean ± SD, n = 3. Statistical analysis was performed using a one-way ANOVA with 
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Dunnett’s multiple comparisons test; * P < 0.05 compared to control. C: In vitro scratch assays 
were performed on MDA-MB-231 cells in the absence (control, 0) and presence of AMTB (3 µM, 
30 µM). AMTB (30 µM) decreased the migration of MDA-MB-231 cells by ~20%. Representative 
images from one experiment after initial scratch (0 h) and 24 h post-treatment. Bar graph represents 
the relative confluency of each treatment group normalised to control well (24 h with media only); 
mean ± SD, n=3, * P < 0.05. 
 
 
Table 1: TRPM8 mRNA are very low or undetectable in breast cancer cell lines. Molecular 
subtypes, receptor status (estrogen receptor, ER; progesterone receptor, PR (38, 39)) and average CT 
values for TRPM8 and 18S rRNA (housekeeping control) in different breast cancer cell lines, CT > 
35 were assigned not detected (ND); mean ± SD, n=3.  
Cell Line 
Molecular Subtype and 
Receptor Status 
C
T
 TRPM8 C
T
 18S 
HCC1569 Basal, ER-, PR-, HER2+ ND 15.52 ± 0.62 
MCF-7 Luminal, ER+, PR+ ND 15.92 ± 0.42 
MDA-MB-231 Basal, ER-, PR- ND 14.93 ± 0.30 
MDA-MB-468 Basal, ER-, PR- 34.04 ± 0.52 15.53 ± 0.39 
SK-BR-3 Luminal, ER-, PR-, HER2+ 33.34 ± 0.57 14.94 ± 0.11 
T-47D Luminal, ER+, PR+ ND 15.83 ± 0.16 
ZR-75-1 Luminal, ER+, PR- 34.81 ± 0.62 17.13 ± 0.18 
Positive control: TRPM8 cDNA - 12.55 ± 0.05 - 
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AMTB inhibits veratridine-induced effects on membrane potential 
Strikingly, AMTB contains several structural features required for inhibition of voltage-gated 
sodium channels (NaV) by local anesthetics, including a substituted benzene ring, an intermediate 
chain with amide linker, as well as a hydrophilic terminal (Figure 3A and B). In addition to 
structural similarities of AMTB to such compounds, we also observed profound analgesia of 
AMTB after intraplantar administration in animal models of chemotherapy-induced allodynia where 
local anaesthetic provided anti-allodynic effects, but TRPM8 knockout animals lacked a phenotype 
(data not shown) (40). We thus assessed the effect of AMTB on the function of NaV1.1-1.8 using a 
high-throughput fluorescent imaging plate reader (FLIPR) membrane potential assay (Figure 3C). 
AMTB blocked veratridine-induced membrane potential changes at each NaV1 isoform more 
potently than the prototypical NaV blocker lidocaine (Figure 3C and D). The IC50 (~2 - 15 μM) for 
each NaV placed the actions of AMTB on NaVs in a similar concentration range as that reported for 
inhibition of TRPM8 by AMTB (23). Given veratridine has no effect on membrane potential in 
untransfected HEK293 cells (Suppl. Fig 1), and that AMTB did not affect membrane potential in 
HEK cells expressing NaV1.1-1.8 (data not shown and Suppl. Fig 2), these results are consistent 
with inhibition of NaV1.1-1.8 by AMTB. These results, therefore, suggested that one of the 
mechanisms by which AMTB could exert effects on MDA-MB-231 cells is via effects on NaVs. 
Therefore, the presence of NaVs in a panel of breast cancer cell lines representing different 
molecular subtypes was evaluated. 
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Figure 3: AMTB is a non-selective inhibitor of voltage-gated sodium channels (NaV). (A) 
Chemical structure of AMTB (N-(3-aminopropyl)-2-[(3-methylphenyl)methoxy]-N-(2-
thienylmethyl)-benzamide). (B) Chemical structure of lidocaine (N-(2,6-
dimethylphenyl)acetamide). (C) Representative concentration-response curves for AMTB and 
lidocaine in HEK293 cells stably expressing hNaV1.1-1.8. Data are presented as mean ± SEM from 
3-6 wells. (D) pIC50 values for AMTB and lidocaine at hNaV1.1-1.8 obtained from the membrane 
potential assays. Data are presented as mean ± SEM from 3 independent experiments.  
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Differential expression of NaVs in human breast cancer cell lines 
There have been reports of NaVs in human breast cancer cell lines, including the consequences of 
silencing and/or pharmacological inhibition of specific NaV1 isoforms (41-43). However, there has 
been no comprehensive study of NaV1 isoforms across human breast cancer cell lines of different 
molecular subtypes. Our assessment of NaV1.1-1.8 mRNA in luminal, HER2 enriched and basal-
like breast cancer cell lines identified that in contrast to TRPM8, all assessed breast cancer cell lines 
had detectable levels of mRNA for at least one NaV1 isoform. 
 
There were significant differences in the mRNA levels of specific mRNA isoforms between breast 
cancer cells lines. For example, the HER2 enriched basal-like molecular subtype cell line HCC1569 
(38, 39) had the highest levels of NaV1.1 and NaV1.6 mRNA, whereas the basal-like MDA-MB-468 
cell line had the highest levels of NaV1.2. The basal, triple negative MDA-MB-231 cell line (38, 39) 
had the highest levels of NaV1.3, NaV1.5 and NaV1 .7. NaV1.8 was undetected or at the limit 
detection for all breast cancer cell lines examined. Elevated levels of specific NaV1 isoforms is not a 
characteristic specific to basal-like cell lines since the luminal and estrogen receptor positive breast 
cancer cell lines MCF-7 and T47D (38, 39) had the highest levels of NaV1.9 and NaV1.4, 
respectively. Indeed, there was no clear relationship between the expression of a specific NaV 
isoforms and the molecular subtype of the breast cancer cell line or the expression of any specific 
biomarker (e.g. HER2 enriched or the estrogen receptor).  
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Figure 4: Levels of NaV1.1-1.9 mRNA in seven breast cancer cell lines. - ΔCT values (-CT target-
CT 18S) from qPCR analysis of NaV isoforms in a panel of breast cancer cell lines. A more positive 
value is reflective of a greater level of target mRNA. Dots on the x-axis signify the target was 
beyond the designated limit of detection (CT > 35) and was assigned a -ΔCT value of -25. Each dot 
represents an independent biological replicate, (n = 3). See Table 1 for molecular subtypes and 
receptor status of the cell lines used. 
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Discussion 
These studies suggest that basal-like breast tumours express significantly higher levels of TRPM8 
compared to luminal A, B and HER2 enriched subtypes suggesting a possible role for TRPM8 as a 
therapeutic target or biomarker in breast cancer. However, TRPM8 seems to be undetectable in 
many breast cancer cell lines. Our studies using breast cancer cell lines that do not express TRPM8 
suggest that the widely used TRPM8 inhibitor AMTB may exert effects via non-TRPM8 
mechanisms in some models, specifically through inhibition NaVs. Hence, AMTB like the non-
selective TRPM8 activator menthol should be used with caution in studies of TRPM8 because of 
non-TRPM8 mediated effects (44, 45). 
 
An association between TRPM8 and breast cancer was first evident in the initial reports of TRPM8 
(previously known as Trp-p8), where TRPM8 levels were reported to be elevated in breast tumours 
compared to corresponding normal tissues (15). TRPM8 overexpression has also been reported in 
human breast ductal adenocarcinoma compared to adjacent non-tumoural tissue using RT-PCR and 
immunohistochemistry (46). Despite these reports and the importance of breast cancer subtypes (47, 
48), there has been no published assessment of TRPM8 in the context of breast cancer molecular 
subtypes. Our studies suggest that elevated TRPM8 mRNA is a feature of basal breast cancers, 
which represent a subtype with significant overlap with triple negative breast cancer cancers (49), 
which have been identified as a subtype requiring new therapeutic approaches (9, 10). However, 
future assessment of TRPM8 in basal breast cancer may be challenging since we found that TRPM8 
is undetectable in the basal-like MDA-MB-231 breast cancer cell line and was also undetectable or 
at the limit of detection in all the other breast cancers (luminal and basal-like) that we examined. 
This result is in contrast to other studies of TRPM8 in human breast cancer cell lines (21, 22). 
Clearly, our quantitative RT-PCR assay is distinct from both the endpoint PCR assay and western 
blots used in the studies of Chodon et al (21). Indeed, it is notable that the short 16 and 17 bp PCR 
primers used in Chodon et al’s study to assess TRPM8 expression lack specificity to this gene as 
both primers bind to the mRNAs of several genes. Liu et al (22), reported a relatively consistently 
high level of TRPM8 protein by western blot in a panel of 6 breast cancer cell lines, although the 
antibody used was not specified. We have tried to resolve this disparity by examining RNA-Seq 
data from an MDA-MB-231 line cultured in a different laboratory. Analysis of sequencing runs 
from two independent samples with 13,925,285 and 40,037,205 aligned reads found totals of 0 and 
3 sequencing reads, respectively mapping to TRPM8 (data not shown), suggesting that this gene is 
silent in MDA-MB-231 cells and raising questions about the specificity of the antibody used which 
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was interpreted as showing very robust expression of TRPM8 protein in this particular cell line 
(22). 
 
Variations in the origin and batch of foetal bovine serum used in cell culture could also alter 
TRPM8 gene expression as has been reported for other genes (50). The relatively few studies of 
TRPM8 in breast cancer cell lines may be reflective of issues related to TRPM8 expression. The 
loss of TRPM8 in cultured breast cancer cell lines is not totally unexpected. Genes that have roles in 
proliferation, angiogenesis, migration and invasion can display very different expression profiles in 
2D in vitro cell cultures compared to in vivo conditions (51-53), leading to differences in mRNA 
and protein levels between clinical samples and cell lines (54). In prostate cancer  (where TRPM8 is 
highly expressed in androgen-dependent tumours (15, 28, 30, 55), TRPM8 mRNA levels in primary 
cell cultures of prostate tumours are reduced when cells are cultured for extended periods of time (> 
20 days) (56). In any case, the absence of detectable levels of TRPM8 mRNA in breast cancer cells 
indicated that AMTB was not exerting its effects on the proliferation and migration of breast cancer 
cells via the TRPM8 ion channel in our studies. These findings highlight the need for careful 
validation of results from experiments using pharmacological modulators due to unknown off-target 
effects. Examples of off-target effects with other TRP channel inhibitors include the selective 
TRPV1 channel activator capsaicin, which can modulate NaV and potassium channel function when 
used at high concentrations (micro – millimolar) (57, 58).  
 
AMTB possesses several structural features which are recognised as important for the activity of 
local anesthetics at NaV channels, such as a substituted benzene ring, an intermediate chain with 
amide linker, as well as a hydrophilic terminal. In addition, we have previously observed in vivo 
analgesic effects of AMTB that appeared to be mediated via inhibition of NaV channels rather than 
TRPM8 (unpublished data). Accordingly, findings from our study indicate that AMTB (pIC50 ~ 
4.83 – 5.69 at NaVs) is a more potent inhibitor of NaVs (NaV1.1-1.8) than lidocaine (IC50 = 210 µM 
/ pIC50 ~ 3.67) (59). Further studies would be required to confirm inhibition of NaV isoforms using 
electrophysiological approaches, and to assess whether AMTB also binds to the local anesthetic site 
on NaV channels. 
 
There was no obvious relationship between the expression profile of NaV isoforms and common 
breast cancer subtype markers (e.g. estrogen receptor and HER2 overexpression). However, the 
basal breast cancer cell lines HCC1569 and MDA-MB-231 showed high mRNA levels for NaV1.5 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
17 
compared to the luminal breast cancer cell lines assessed. Studies assessing protein levels of Nav 
channels in breast cancer cell lines would enhance our understanding of potential differences 
between breast cancer cell lines. NaVs are normally found in excitable tissues (60) but have also 
been reported in cancer cells (61). Altered expression of NaVs have been described in prostate (62), 
breast (43), lung (63), cervical (64), colon (65) and ovarian cancers (66). In many of these cancers, 
altered mRNA and/or protein expression correlates with metastatic /invasive potential (67). For 
example, NaV1.8 is highly expressed in several prostate cancer cell lines (DU-145, PC-3 and PC-
3M) and its expression correlates with more advanced pathologic stages of the disease (62) In breast 
cancer, the upregulation of NaV1.5 and the neonatal splice variant of NaV1.5 (nNaV1.5) is linked to 
metastatic potential (43, 68). Indeed, the highly metastatic MDA-MB-231 breast cancer cell line 
(38, 39) has been reported to have greater levels of NaV1.5 (~1,800 times higher) compared to the 
weakly metastatic MCF-7 cell line, which was consistent with our data (41, 69, 70). Moreover, 
NaV1.5 levels appear lower in non-tumourigenic cells (41, 69, 70) and increased expression of 
NaV1.5 mRNA is a feature of some breast tumours (71).  
 
Conclusion 
These studies provide evidence that some of the effects of AMTB are not mediated by TRPM8 but 
instead occur via inhibition of NaVs. Despite a possible association between TRPM8 levels in basal 
breast cancers, the absence of TRPM8 in commonly used breast cancer cell lines may represent 
challenges in defining the applicability of TRPM8 as a therapeutic target in this breast cancer 
subtype. 
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